NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
ORCL
Oracle Corporation
ORCL has the edge over NVO overall, supported by stronger valuation and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ORCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
ORCL's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ORCL in the historical PE scenario, which offers more potential upside but is not a forecast.
ORCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $127 | — |
| Cheap | 19x | $119 | -6.8% |
| Current | 20x | $127 | — |
| Fair | 30x | $189 | +49% |
| Expensive | 39x | $247 | +94% |
Historical ranges are pointers, not guarantees.
ORCL's PE is in its cheap range at 20x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ORCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| High |
ORCL has the edge over NVO on the outlook, with more favorable earnings expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ORCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.53 | +34% |
| Q3 2026 | $6.38 | +48% |
| Q2 2026 | $5.83 | +34% |
| Q1 2026 | $5.57 | +31% |
| Q4 2025 | $5.32 | +30% |
| Q3 2025 | $4.32 | +11% |
| Q2 2025 | $4.34 | +17% |
| Q1 2025 | $4.26 | +12% |
| Q4 2024 | $4.09 | +13% |
ORCL has the edge over NVO on earnings, with stronger typical year-over-year growth.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
ORCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.3B | +30% |
| Q2 2026 | $19.2B | +21% |
| Q1 2026 | $17.2B | +22% |
| Q4 2025 | $16.1B | +14% |
| Q3 2025 | $14.9B | +12% |
| Q2 2025 | $15.9B | +11% |
| Q1 2025 | $14.1B | +6.4% |
| Q4 2024 | $14.1B | +8.6% |
ORCL's revenue has grown year over year for 13 quarters in a row: $19.3B last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | +6.1 points |
| Q2 2026 | 32% | -0.2 points |
| Q1 2026 | 32% | +0.9 points |
| Q4 2025 | 29% | -0.6 points |
| Q3 2025 | 29% | -1.3 points |
| Q2 2025 | 32% | -0.7 points |
| Q1 2025 | 31% | +2.6 points |
| Q4 2024 | 30% | +2 points |
ORCL has the edge over NVO on profitability, with a higher operating margin.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ORCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.4B | -$5B |
| Q2 2026 | -$1.9B | +$1.1B |
| Q1 2026 | -$11.5B | -16275% |
| Q4 2025 | -$10B | -$7.3B |
| Q3 2025 | -$362M | -107% |
| Q2 2025 | -$2.9B | -189% |
| Q1 2025 | $71M | -98% |
| Q4 2024 | -$2.7B | -$1.7B |
ORCL has burned cash in seven of the last eight quarters: −$28.7B over the past year, against −$5.9B the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ORCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ORCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +86M shares |
| 1 year | +3.1% | +91M shares |
| 3 years | +6.3% | +177M shares |
| 5 years | +4.9% | +139M shares |
| Available history | -9.9% | -331M shares |
ORCL has 3B diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $95M |
| Q2 2025 | $150M |
| Q1 2025 | $150M |
| Q4 2024 | $150M |
| Q3 2024 | $150M |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ORCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.2x | Very low |
ORCL has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ORCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 23.0 | Neutral |
ORCL's weekly RSI is 42 (neutral) and its Stochastic is 23 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ORCL on valuation relative to its sector.
ORCL PE vs Technology Sector
| Metric | ORCL | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 28% below |
| PE % | 28 | 35 | 7 pts below |
ORCL is trading at 20x earnings, a 28% discount to the Technology sector's median of 28x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over ORCL on trend strength, trading above more of its moving averages.
ORCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $131.1 | 3.1% below |
| 20 week MA | $137.6 | 7.7% below |
| 50 week MA | $160.3 | 21% below |
| 100 week MA | $181.4 | 30% below |
| 200 week MA | $151.9 | 16% below |
ORCL is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over ORCL on returns for 2026, with the stronger performance.
ORCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $53.5 | $65.0 | +22% |
| 2021 | $65.0 | $89.7 | +38% |
| 2022 | $89.7 | $80.9 | -9.9% |
| 2023 | $80.9 | $105.4 | +30% |
| 2024 | $105.4 | $169.0 | +60% |
| 2025 | $169.0 | $198.0 | +17% |
| 2026 YTD | $198.0 | $127.1 | -36% |
ORCL is down 36% so far in 2026, after finishing higher in five of the previous six years.